Skip to main content
Top
Published in: Obesity Surgery 4/2024

24-02-2024 | Cholecystectomy | Original Contributions

The Management of Biliary Disease in Patients with Severe Obesity Undergoing Metabolic and Bariatric Surgery—An International Expert Survey

Authors: Mohammad Kermansaravi, Scott Shikora, Bruno Dillemans, Marina Kurian, Teresa LaMasters, Ramon Vilallonga, Gerhard Prager, Sonja Chiappetta, MOGIPSO Collaborators

Published in: Obesity Surgery | Issue 4/2024

Login to get access

Abstract

Objective

This study aimed to survey international experts in metabolic and bariatric surgery (MBS) to improve and consolidate the management of biliary disease in patients with severe obesity undergoing MBS.

Background

Obesity and rapid weight loss after MBS are risk factors for the development of gallstones. Complications, such as cholecystitis, acute cholangitis, and biliary pancreatitis, are potentially life-threatening, and no guidelines for the proper management of gallstone disease exist.

Methods

An international scientific team designed an online confidential questionnaire with 26 multiple-choice questions. The survey was answered by 86 invited experts (from 38 different countries), who participated from August 1, 2023, to September 9, 2023.

Results

Two-thirds of experts (67.4%) perform concomitant cholecystectomy in symptomatic gallstones during MBS. Half of experts (50%) would wait 6–12 weeks between both surgeries with an interval approach. Approximately 57% of the experts prescribe ursodeoxycholic acid (UDCA) prophylactically after MBS, and most recommend a 6-month course. More than the half of the experts (59.3%/53.5%) preferred laparoscopic assisted transgastric ERCP as the approach for treating CBD stones in patients who previously had RYGB/OAGB.

Conclusion

Concomitant cholecystectomy is preferred by the experts, although evidence in the literature reports an increased complication rate. Prophylactic UDCA should be recommended to every MBS patient, even though the current survey demonstrated that not all experts are recommending it. The preferred approach for treating common bile duct stones is a laparoscopic assisted transgastric ERCP after gastric bypass. The conflicting responses will need more scientific work and clarity in the future.

Graphical Abstract

Literature
1.
go back to reference Unalp-Arida A, Der JS, Ruhl CE. Longitudinal study of comorbidities and clinical outcomes in persons with gallstone disease using electronic health records. J Gastrointest Surg. 2023;27(12):2843–56.CrossRefPubMed Unalp-Arida A, Der JS, Ruhl CE. Longitudinal study of comorbidities and clinical outcomes in persons with gallstone disease using electronic health records. J Gastrointest Surg. 2023;27(12):2843–56.CrossRefPubMed
2.
go back to reference Boerlage TCC, Haal S, Maurits de Brauw L, et al. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial). BMC Gastroenterol. 2017;17(1):164.CrossRefPubMedPubMedCentral Boerlage TCC, Haal S, Maurits de Brauw L, et al. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial). BMC Gastroenterol. 2017;17(1):164.CrossRefPubMedPubMedCentral
3.
go back to reference Clapp B, Lee I, Liggett E, et al. Are concomitant operations during bariatric surgery safe? An analysis of the MBSAQIP Database. Obes Surg. 2020;30(11):4474–81.CrossRefPubMed Clapp B, Lee I, Liggett E, et al. Are concomitant operations during bariatric surgery safe? An analysis of the MBSAQIP Database. Obes Surg. 2020;30(11):4474–81.CrossRefPubMed
4.
go back to reference Amorim-Cruz F, Santos-Sousa H, Ribeiro M, et al. Risk and prophylactic management of gallstone disease in bariatric surgery: a systematic review and a Bayesian meta-analysis. J Gastrointest Surg : Off J Soc Surg Aliment Tract. 2023;27(2):433–48.CrossRef Amorim-Cruz F, Santos-Sousa H, Ribeiro M, et al. Risk and prophylactic management of gallstone disease in bariatric surgery: a systematic review and a Bayesian meta-analysis. J Gastrointest Surg : Off J Soc Surg Aliment Tract. 2023;27(2):433–48.CrossRef
5.
go back to reference Doulamis IP, Michalopoulos G, Boikou V, et al. Concomitant cholecystectomy during bariatric surgery: the jury is still out. Am J Surg. 2019;218(2):401–10.CrossRefPubMed Doulamis IP, Michalopoulos G, Boikou V, et al. Concomitant cholecystectomy during bariatric surgery: the jury is still out. Am J Surg. 2019;218(2):401–10.CrossRefPubMed
6.
go back to reference Coogan AC, Williams MD, Krishnan V, et al. Ursodiol prescriptions following bariatric surgery: national prescribing trends and outcomes. Obes Surg. 2023;33(8):2361–7.CrossRefPubMed Coogan AC, Williams MD, Krishnan V, et al. Ursodiol prescriptions following bariatric surgery: national prescribing trends and outcomes. Obes Surg. 2023;33(8):2361–7.CrossRefPubMed
7.
go back to reference Mulliri A, Menahem B, Alves A, et al. Ursodeoxycholic acid for the prevention of gallstones and subsequent cholecystectomy after bariatric surgery: a meta-analysis of randomized controlled trials. J Gastroenterol. 2022;57(8):529–39.CrossRefPubMed Mulliri A, Menahem B, Alves A, et al. Ursodeoxycholic acid for the prevention of gallstones and subsequent cholecystectomy after bariatric surgery: a meta-analysis of randomized controlled trials. J Gastroenterol. 2022;57(8):529–39.CrossRefPubMed
8.
go back to reference Haal S, Guman MSS, Boerlage TCC, et al. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial. Lancet Gastroenterol Hepatol. 2021;6(12):993–1001.CrossRefPubMed Haal S, Guman MSS, Boerlage TCC, et al. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial. Lancet Gastroenterol Hepatol. 2021;6(12):993–1001.CrossRefPubMed
9.
go back to reference Yuan S, Gill D, Giovannucci EL, et al. Obesity, type 2 diabetes, lifestyle factors, and risk of gallstone disease: a Mendelian randomization investigation. Clin Gastroenterol Hepatol : Off Clin Pract J Am Gastroenterol Assoc. 2022;20(3):e529–37.CrossRef Yuan S, Gill D, Giovannucci EL, et al. Obesity, type 2 diabetes, lifestyle factors, and risk of gallstone disease: a Mendelian randomization investigation. Clin Gastroenterol Hepatol : Off Clin Pract J Am Gastroenterol Assoc. 2022;20(3):e529–37.CrossRef
10.
go back to reference Anveden Å, Peltonen M, Näslund I, et al. Long-term incidence of gallstone disease after bariatric surgery: results from the nonrandomized controlled Swedish Obese Subjects study. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2020;16(10):1474–82.CrossRef Anveden Å, Peltonen M, Näslund I, et al. Long-term incidence of gallstone disease after bariatric surgery: results from the nonrandomized controlled Swedish Obese Subjects study. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2020;16(10):1474–82.CrossRef
11.
go back to reference Kumaravel A, Zelisko A, Schauer P, et al. Acute pancreatitis in patients after bariatric surgery: incidence, outcomes, and risk factors. Obes Surg. 2014;24(12):2025–30.CrossRefPubMed Kumaravel A, Zelisko A, Schauer P, et al. Acute pancreatitis in patients after bariatric surgery: incidence, outcomes, and risk factors. Obes Surg. 2014;24(12):2025–30.CrossRefPubMed
12.
go back to reference Benarroch-Gampel J, Lairson DR, Boyd CA, et al. Cost-effectiveness analysis of cholecystectomy during Roux-en-Y gastric bypass for morbid obesity. Surgery. 2012;152(3):363–75.CrossRefPubMed Benarroch-Gampel J, Lairson DR, Boyd CA, et al. Cost-effectiveness analysis of cholecystectomy during Roux-en-Y gastric bypass for morbid obesity. Surgery. 2012;152(3):363–75.CrossRefPubMed
13.
go back to reference Yildirim K, Karabicak I, Gursel MF, et al. The outcome of concomitant cholecystectomy with bariatric surgery: a retrospective cohort study. Ann Med Surg (2012). 2023;85(4):718–21.CrossRef Yildirim K, Karabicak I, Gursel MF, et al. The outcome of concomitant cholecystectomy with bariatric surgery: a retrospective cohort study. Ann Med Surg (2012). 2023;85(4):718–21.CrossRef
14.
go back to reference Leyva-Alvizo A, Arredondo-Saldaña G, Leal-Isla-Flores V, et al. Systematic review of management of gallbladder disease in patients undergoing minimally invasive bariatric surgery. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2020;16(1):158–64.CrossRef Leyva-Alvizo A, Arredondo-Saldaña G, Leal-Isla-Flores V, et al. Systematic review of management of gallbladder disease in patients undergoing minimally invasive bariatric surgery. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2020;16(1):158–64.CrossRef
15.
go back to reference Dirnberger AS, Schneider R, Slawik M, et al. Management of gallstone disease prior to and after metabolic surgery: a single-center observational study. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2022;18(2):182–8.CrossRef Dirnberger AS, Schneider R, Slawik M, et al. Management of gallstone disease prior to and after metabolic surgery: a single-center observational study. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2022;18(2):182–8.CrossRef
16.
go back to reference Wood SG, Kumar SB, Dewey E, et al. Safety of concomitant cholecystectomy with laparoscopic sleeve gastrectomy and gastric bypass: a MBSAQIP analysis. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2019;15(6):864–70.CrossRef Wood SG, Kumar SB, Dewey E, et al. Safety of concomitant cholecystectomy with laparoscopic sleeve gastrectomy and gastric bypass: a MBSAQIP analysis. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2019;15(6):864–70.CrossRef
17.
go back to reference de Lucena AVS, Cordeiro GG, Leão LHA, et al. Cholecystectomy concomitant with bariatric surgery: safety and metabolic effects. Obes Surg. 2022;32(4):1093–102.CrossRefPubMed de Lucena AVS, Cordeiro GG, Leão LHA, et al. Cholecystectomy concomitant with bariatric surgery: safety and metabolic effects. Obes Surg. 2022;32(4):1093–102.CrossRefPubMed
18.
go back to reference Habeeb T, Kermansaravi M, Giménez ME, et al. Sleeve gastrectomy and cholecystectomy are safe in obese patients with asymptomatic cholelithiasis. A Multicenter Randomized Trial. World J Surg. 2022;46(7):1721–33.CrossRefPubMedPubMedCentral Habeeb T, Kermansaravi M, Giménez ME, et al. Sleeve gastrectomy and cholecystectomy are safe in obese patients with asymptomatic cholelithiasis. A Multicenter Randomized Trial. World J Surg. 2022;46(7):1721–33.CrossRefPubMedPubMedCentral
19.
go back to reference Allatif REA, Mannaerts GHH, Al Afari HST, et al. Concomitant cholecystectomy for asymptomatic gallstones in bariatric surgery-safety profile and feasibility in a large tertiary referral bariatric center. Obes Surg. 2022;32(2):295–301.CrossRefPubMed Allatif REA, Mannaerts GHH, Al Afari HST, et al. Concomitant cholecystectomy for asymptomatic gallstones in bariatric surgery-safety profile and feasibility in a large tertiary referral bariatric center. Obes Surg. 2022;32(2):295–301.CrossRefPubMed
20.
go back to reference Cunningham RM, Jones KT, Kuhn JE, et al. Asymptomatic cholelithiasis and bariatric surgery: a comprehensive long-term analysis of the risks of biliary disease in patients undergoing primary Roux-en-Y gastric bypass. Obes Surg. 2021;31(3):1249–55.CrossRefPubMed Cunningham RM, Jones KT, Kuhn JE, et al. Asymptomatic cholelithiasis and bariatric surgery: a comprehensive long-term analysis of the risks of biliary disease in patients undergoing primary Roux-en-Y gastric bypass. Obes Surg. 2021;31(3):1249–55.CrossRefPubMed
21.
go back to reference Xia C, Wang M, Lv H, et al. The safety and necessity of concomitant cholecystectomy during bariatric surgery in patients with obesity: a systematic review and meta-analysis. Obes Surg. 2021;31(12):5418–26.CrossRefPubMed Xia C, Wang M, Lv H, et al. The safety and necessity of concomitant cholecystectomy during bariatric surgery in patients with obesity: a systematic review and meta-analysis. Obes Surg. 2021;31(12):5418–26.CrossRefPubMed
23.
go back to reference Ohta M, Tada K, Endo Y, et al. Port-sharing techniques for laparoscopic cholecystectomy and sleeve gastrectomy. Surg Today. 2021;51(12):1996–9.CrossRefPubMed Ohta M, Tada K, Endo Y, et al. Port-sharing techniques for laparoscopic cholecystectomy and sleeve gastrectomy. Surg Today. 2021;51(12):1996–9.CrossRefPubMed
24.
go back to reference Coupaye M, Calabrese D, Sami O, et al. Evaluation of incidence of cholelithiasis after bariatric surgery in subjects treated or not treated with ursodeoxycholic acid. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2017;13(4):681–5.CrossRef Coupaye M, Calabrese D, Sami O, et al. Evaluation of incidence of cholelithiasis after bariatric surgery in subjects treated or not treated with ursodeoxycholic acid. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2017;13(4):681–5.CrossRef
25.
go back to reference Pizza F, D’Antonio D, Lucido FS, et al. The role of ursodeoxycholic acid (UDCA) in cholelithiasis management after one anastomosis gastric bypass (OAGB) for morbid obesity: results of a monocentric randomized controlled trial. Obes Surg. 2020;30(11):4315–24.CrossRefPubMed Pizza F, D’Antonio D, Lucido FS, et al. The role of ursodeoxycholic acid (UDCA) in cholelithiasis management after one anastomosis gastric bypass (OAGB) for morbid obesity: results of a monocentric randomized controlled trial. Obes Surg. 2020;30(11):4315–24.CrossRefPubMed
26.
go back to reference Sucandy I, Abulfaraj M, Naglak M, et al. Risk of biliary events after selective cholecystectomy during biliopancreatic diversion with duodenal switch. Obes Surg. 2016;26(3):531–7.CrossRefPubMed Sucandy I, Abulfaraj M, Naglak M, et al. Risk of biliary events after selective cholecystectomy during biliopancreatic diversion with duodenal switch. Obes Surg. 2016;26(3):531–7.CrossRefPubMed
27.
go back to reference Fearon NM, Kearns EC, Kennedy CA, et al. The impact of ursodeoxycholic acid on gallstone disease after bariatric surgery: a meta-analysis of randomized control trials. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2022;18(1):77–84.CrossRef Fearon NM, Kearns EC, Kennedy CA, et al. The impact of ursodeoxycholic acid on gallstone disease after bariatric surgery: a meta-analysis of randomized control trials. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2022;18(1):77–84.CrossRef
28.
go back to reference Haal S, Guman MSS, de Brauw LM, et al. Cost-effectiveness of ursodeoxycholic acid in preventing new-onset symptomatic gallstone disease after Roux-en-Y gastric bypass surgery. Br J Surg. 2022;109(11):1116–23.CrossRefPubMedPubMedCentral Haal S, Guman MSS, de Brauw LM, et al. Cost-effectiveness of ursodeoxycholic acid in preventing new-onset symptomatic gallstone disease after Roux-en-Y gastric bypass surgery. Br J Surg. 2022;109(11):1116–23.CrossRefPubMedPubMedCentral
29.
go back to reference Hall L, Halle-Smith J, Evans R, Toogood G, Wiggins T, Markar SR, Kapoulas S, Super P, Tucker O, McKay SC. Ursodeoxycholic acid in the management of symptomatic gallstone disease: systematic review and clinician survey. BJS Open. 2023;7(2):zrac152.CrossRefPubMedPubMedCentral Hall L, Halle-Smith J, Evans R, Toogood G, Wiggins T, Markar SR, Kapoulas S, Super P, Tucker O, McKay SC. Ursodeoxycholic acid in the management of symptomatic gallstone disease: systematic review and clinician survey. BJS Open. 2023;7(2):zrac152.CrossRefPubMedPubMedCentral
30.
go back to reference Della Penna A, Lange J, Hilbert J, et al. Ursodeoxycholic acid for 6 months after bariatric surgery is impacting gallstone associated morbidity in patients with preoperative asymptomatic gallstones. Obes Surg. 2019;29(4):1216–21.CrossRefPubMed Della Penna A, Lange J, Hilbert J, et al. Ursodeoxycholic acid for 6 months after bariatric surgery is impacting gallstone associated morbidity in patients with preoperative asymptomatic gallstones. Obes Surg. 2019;29(4):1216–21.CrossRefPubMed
31.
go back to reference Banerjee N, Parepally M, Byrne TK, et al. Systematic review of transgastric ERCP in Roux-en-Y gastric bypass patients. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2017;13(7):1236–42.CrossRef Banerjee N, Parepally M, Byrne TK, et al. Systematic review of transgastric ERCP in Roux-en-Y gastric bypass patients. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2017;13(7):1236–42.CrossRef
32.
go back to reference Aiolfi A, Asti E, Rausa E, et al. Trans-gastric ERCP after Roux-en-Y gastric bypass: systematic review and meta-analysis. Obes Surg. 2018;28(9):2836–43.CrossRefPubMed Aiolfi A, Asti E, Rausa E, et al. Trans-gastric ERCP after Roux-en-Y gastric bypass: systematic review and meta-analysis. Obes Surg. 2018;28(9):2836–43.CrossRefPubMed
Metadata
Title
The Management of Biliary Disease in Patients with Severe Obesity Undergoing Metabolic and Bariatric Surgery—An International Expert Survey
Authors
Mohammad Kermansaravi
Scott Shikora
Bruno Dillemans
Marina Kurian
Teresa LaMasters
Ramon Vilallonga
Gerhard Prager
Sonja Chiappetta
MOGIPSO Collaborators
Publication date
24-02-2024
Publisher
Springer US
Published in
Obesity Surgery / Issue 4/2024
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-024-07101-y

Other articles of this Issue 4/2024

Obesity Surgery 4/2024 Go to the issue